主要目的：在既往接受过针对广泛期小细胞肺癌的一线含铂方案全身治疗，并在一线治疗过程中或一线治疗结束后≤6个月复发或进展的广泛期小细胞肺癌患者中，评价JK1201I对比注射用盐酸托泊替康治疗方案的有效性。次要目的： 1)评价JK1201I对比注射用盐酸托泊替康，在既往接受过针对广泛期小细胞肺癌的一线含铂方案全身治疗，并在一线治疗过程中或一线治疗结束后≤6个月复发或进展的广泛期小细胞肺癌患者中的安全性； 2）评价JK1201I在既往接受过针对广泛期小细胞肺癌的一线含铂方案全身治疗，并在一线治疗过程中或一线治疗结束后≤6个月复发或进展的广泛期小细胞肺癌患者中的群体药代动力学特性。

开始日期2024-09-29

申办/合作机构

天津键凯科技有限公司

NCT06575127 / Recruiting临床2期IIT

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC). FOLFOXIRI, though effective, is known for its high toxicity, necessitating close monitoring and dose adjustments. .
The primary endpoint is to assess the impact on the objective response rate and evaluate both acute and delayed toxicity. The secondary endpoints include studying the treatment's effectiveness as conversion therapy, along with disease-free survival (DFS) and overall survival (OS). The tertiary endpoint focuses on evaluating predictive and prognostic factors of significance.
This study seeks to balance the efficacy of FOLFOXIRI with a modified dose to minimize toxicity while maintaining therapeutic benefits, providing a potentially safer and effective option for patients with MCRC.

开始日期2024-08-17

申办/合作机构

Al-Azhar University

100 项与聚乙二醇伊立替康相关的临床结果

登录后查看更多信息

100 项与聚乙二醇伊立替康相关的转化医学

登录后查看更多信息

100 项与聚乙二醇伊立替康相关的专利（医药）

登录后查看更多信息

239

项与聚乙二醇伊立替康相关的文献（医药）

2024-09-01·Perfusion

Administration of a new nano delivery system coated with Tirofiban to prevent early thrombosis of vein graft

Article

作者: Wang, Bolin ; Wang, Yapei ; Yu, Yang ; Dong, Shuo ; Gao, Mingxin ; Ding, Xiaohang ; Lian, Xiaodong ; Yu, Wenyuan

Objective:

To verify the administration of a new nano delivery system coated with Tirofiban on preventing early thrombosis in vein graft.

Methods:

Forty New Zealand white rabbits were randomly divided into five groups with eight rabbits in each group. The rabbits of all groups underwent jugular vein transplantation, except group I with only neck opening and closing operation. Vein grafts of group II were preprocessed by intravenous injection of normal saline; group III were preprocessed by tirofiban alone; group IV were preprocessed by unloaded nanoparticles of PLGA-PEG; group V were preprocessed by PLGA-PEG coated with tirofiban. Coagulation and platelet function of peripheral and vein graft blood were detected at 1, 2, 4, 12 h and 1, 3, 7, 10, 14 days after operation. Patency rate of vein graft and blood flow index were measured by vascular ultrasound at third, seventh, 10th, and 14th days after operation; two rabbits in each group were randomly sacrificed at the corresponding time of detection. Pathological differences of vein grafts were observed by HE stainin.

Results:

The patency rate of vein grafts in group V was significantly higher than that in group II to IV. The platelet and platelet aggregation rate in group V were inhibited in vein graft blood significantly. The post-operative PT and APTT in vein graft blood in group V were increased obviously while the FBG, D-dimer and FDP were significantly inhibited. Except group I, the lumen loss rate of vein grafts in group V was significantly lower than that in other groups, and vein graft blood in group V had a significant lower expression of platelet P-selectin and GP IIb/IIIa receptor than that in other groups.

Conclusion:

This study proves that PEG-PLGA coated with tirofiban can effectively prevent early vein graft stenosis from thrombosis by inhibition of platelet function, coagulation function.

2024-09-01·Cancer Medicine

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer

Article

作者: Shi, Jinsheng ; Zhao, Xuan ; Li, Xuefei ; Zhao, Yanqiu ; Nie, Ligong ; Fang, Jian ; Yu, Guohua ; Zang, Aimin ; Long, Jieran ; Wu, Lin

Abstract:

Purpose:

To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients.

Methods:

According to the “3 + 3” dose‐escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m2 once every 3 weeks for four cycles. Progression‐free survival (PFS), overall survival (OS), median progression‐free survival (mPFS), and median overall survival (mOS) were evaluated. The Kaplan–Meier method was used to analyze PFS and overall OS. Brookmeyer and Crowley's method was used for mPFS and mOS.

Results:

This study included 29 patients with stage III–IV SCLC (stage IIIa, n = 1; stage IIIb, n = 1; and stage IV, n = 27). Of these, 26 patients were enrolled in the 180 mg/m2 dose group, and 3 patients were enrolled in the 220 mg/m2 dose group. No dose‐limiting toxicity (DLT) was noted during the first 28 days of treatment. Grade 3 or higher adverse events were recorded in the 180 mg/m2 group, including diarrhea (11.5%, 3/26), neutropenia (7.7%, 2/26), and leukopenia (7.7%, 2/26). In the 220 mg/m2 group, one patient (33.3%, 1/3) experienced neutropenia or leukopenia. In the 180 mg/m2 group, 38.5% (10/26) of patients achieved an objective response rate (ORR), with a disease control rate (DCR) of 73.1% (19/26). The mPFS and mOS were 3.4 and 12.1 months, respectively. In the 220 mg/m2 group, one patient had stable disease, and one had progressive disease (PD). The ORR, DCR, mPFS, and mOS were 0% (0/3) and 33.3% (1/3), 2.7 months and 2.7 months, respectively.

Conclusion:

JK1201I exhibits promising efficacy and relatively low toxicities as a second‐line monotherapy for SCLC, warranting further large‐scale clinical studies to evaluate its efficacy in greater detail.

2024-04-02·Journal of liposome research

Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization, in vitro and in vivo assessment

Article

作者: Jain, Sanjay K. ; Yadav, Vivek ; Jain, Sanyog ; Raikwar, Sarjana

The object of the current study was to develop and evaluate trastuzumab-conjugated Paclitaxel (PTX) and Elacridar (ELA)-loaded PEGylated pH-sensitive liposomes (TPPLs) for site-specific delivery of an anticancer drug. In this study, paclitaxel is used as an anticancer drug which promotes microtubules polymerization and arrest cell cycle progression at mitosis and subsequently leading to cell death. The single use of PTX causes multiple drug resistance (MDR) and results failure of the therapy. Hence, the combination of PTX and P-glycoprotein inhibitor (ELA) are used to achieve maximum therapeutic effects of PTX. Moreover, monoclonal antibody (trastuzumab) is used as ligand for the targeting the drug bearing carriers to BC. Thus, trastuzumab anchored pH-sensitive liposomes bearing PTX and ELA were developed using thin film hydration method and Box-Behnken Design (BBD) for optimizing various formulation variables. The optimized liposomes undergo characterization such as vesicle size, PDI, and zeta potential, which were observed to be 122 ± 2.14 nm, 0.224, and -15.5 mV for PEGylated pH-sensitive liposomes (PEG-Ls) and 134 ± 1.88 nm, 0.238, and -13.98 mV for TPPLs, respectively. The results of the in vitro drug release study of both formulations (PEG-Ls and TPPLs) showed enhanced percentage drug release at an acidic pH 5 as compared to drug release at a physiological pH 7.4. Further, the in vitro cytotoxicity studies were performed in the SK-BR-3 and MDA-MB-231 cell lines. The cellular uptake study of FITC-loaded TPPLs in SK-BR-3 cells showed greater uptake than FITC-loaded PEG-Ls, while in MDA-MB-231 cells there was no significant difference in cell uptake between FITC-loaded TPPLs and FITC-loaded PEG-Ls. Hence, it can be concluded that the HER-2 overexpressing cancer cell line (SK-BR-3) was showed better cytotoxicity and cell uptake of TPPLs than the cells that expressed low levels of HER2 (MDA-MB-231). The in vivo tumor regression study, TPPLs showed significantly more tumor burden reduction i.e. up ∼74% as compared to other liposomes after 28 days. Furthermore, the in vivo studies of TPPLs showed a minimal toxicity profile, minimal hemolysis, higher tumor tissue distribution, and superior antitumor efficacy as compared to other formulations. These studies confirmed that TPPLs are a safe and efficacious treatment for breast cancer.

项与聚乙二醇伊立替康相关的新闻（医药）

2024-12-02

·access wire

Alligator Sharpens Focus on Mitazalimab and Announces Cost Reduction Program to Maximize Long-Term Value Creation

Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussionsPlanned reduction of workforce, mainly within Discovery and Non-Clinical unitExpected annual cash savings of at least SEK 65 millionWill continue to conduct limited research activities, primarily related to mitazalimabLUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience AB ("Alligator" or the "Company") announced today that it is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that. All other assets under development are under strategic evaluation.Given the unprecedented survival benefits observed in first line metastatic pancreatic cancer, including a near doubling of the overall survival rate at 18 months compared to FOLFORINOX alone, Alligator believes that mitazalimab should advance into Phase 3 for metastatic pancreatic cancer as soon as possible.The planned restructuring remains subject to negotiation with the relevant trade unions and may result in a reduction of approximately 70% of the current workforce, mainly affecting the discovery and non-clinical operations. Once implemented, the restructuring is expected to reduce operational costs by at least SEK 65 million annually. Going forward Alligator will focus on late-stage development with an adequate workforce of approximately 15 FTEs. Furthermore, Alligator will continue to be able to conduct limited research activities, primarily related to mitazalimab, through internal and external resources.Alligator has separately announced the plans for a Rights issue to be completed in Q1 2025. If the Rights issue is fully subscribed, Alligator will have secured financing up until the end of 2025.Alligator is continuing to prepare mitazalimab for Phase 3 development, in parallel with ongoing partnership discussions. It expects to report 24 months follow-up data from the mitazalimab OPTIMIZE-1 Phase 2 trial in Q1 2025. The 24-month timepoint is longer than many other treatments in metastatic pancreatic cancer have shown, as most trials have been stopped earlier as the clinical efficacy was no longer evident and patients had relapsed or died."Being able to report the OPTIMIZE-1 24-month timepoint sets mitazalimab apart and is a clear testimony to its clinical benefit. Because Alligator at that timepoint expects to continue to deliver additional outstanding Phase 2 clinical data for mitazalimab in 1st line pancreatic cancer, we remain laser focused on mitazalimab development and it is our objective to deliver outstanding returns to our shareholders. The cost savings announced today will strengthen our ability to continue developing mitazalimab and enhance the chances to unlock its value by making it more attractive for partnership," said Søren Bregenholt, CEO of Alligator Bioscience. "In order to focus our current resources on mitazalimab, our most important asset,we have no other option than to reduce our earlier stage research and development activities and workforce. We thank our colleagues, who have strived professionally and with great dedication to innovate and deliver on Alligator'smission to develop drugs for patients with hard-to-treat cancers since the Company's inception. We will make the utmost efforts to support the highly talented people affected by this initiative. I am confident they will prove to be important contributors to other innovative organizations."Alligator will notify the Swedish Public Employment Service (Sw. Arbetsförmedlingen) and seek consultations with trade unions regarding the reorganization. Decisions regarding specific employee reductions will take place after the change consultations have been concluded according to local regulations.For further information, please contact:Søren Bregenholt, CEOE-mail: [email protected] Phone: +46 (0) 46 540 82 00Johan Giléus, CFOE-mail: [email protected] Phone: +46 (0) 46 540 82 00This information is information that Alligator Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-02 08:35 CET.About Alligator BioscienceAlligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.For more information, please visit alligatorbioscience.com .AttachmentsAlligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creationSOURCE: Alligator Bioscience

临床2期临床3期

2024-09-11

·GlobeNewswire-Health Care

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literatureOngoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer populationNo drug related discontinuations to date PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer. Median overall survival of 15.6 months is reported in BriaCell’s most recent patients (treated since 2022) vs. 6.7-9.3 months for similar patients reported in the literature (see table below). These patients are being treated with the same Bria-IMT™ formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612) and represent patients enrolled post-COVID when full study activities resumed. This represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023. “Overall survival in patients with heavily pre-treated metastatic breast cancer is very poor,” stated Sara A. Hurvitz, MD, Professor of Medicine, Fred Hutch Cancer Center and University of Washington and BriaCell medical advisory board member. “The BriaCell early data is quite encouraging from both efficacy and tolerability standpoints.” “We wanted to look at the Phase 2 data of those patients who most closely resemble the patients being treated in our ongoing phase 3 study and compare them to similar patients in the literature,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The nearly two-fold overall survival benefit we are seeing with the Bria-IMT™ regimen, together with the similar previously reported approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT™ could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients. We look forward to further clinical development of Bria-IMT™ with the goal of establishing it as a new standard of care for patients with metastatic breast cancer.” “The Bria-IMT™ regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments including immune check point inhibitors and antibody drug conjugates,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “These survival and clinical benefit data support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and drive the ongoing pivotal study of our combination regimen in the treatment of metastatic breast cancer.” The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6) who were treated with the Bria-IMT™ regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed. This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023. Table 1. Comparative Median Overall Survival (OS) and Progression-Free Survival (PFS) in Similar Patients (Interim Analysis Using Kaplan-Meier Estimate) StudyPrior Lines of Therapy (median, range)Number of PatientsOS (months)PFS (months) BriaCell’s Phase 2 study patients who received pivotal Phase 3 study formulation (since 2022)5.5 (2-13)2515.64.1 BriaCell’s Phase 2 study patients who received pivotal Phase 3 study formulation (total)6 (2-13)3713.43.9 Bardia, A. et. al. 1 (TNBC)4 (2-14)2626.91.7 Tripathy D. et. al. 2 (Brain metastases)≥4 in 91%1787.5-7.81.9-2.8 O’Shaughnessy J. et. al. 3non-TNBC at initial diagnosis5 (2-14)766.72.3 O’Shaughnessy J. et. al. 3TNBC at initial diagnosis4 (2-10)1576.91.6 Cortes et. al. 44 (0-13)5949.1-9.31.9-2.5 References Bardia A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473.Tripathy D, et al. Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial. JAMA Oncol. 2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514.O’Shaughnessy J et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646.Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051. PMID: 29481630. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about: the impact of Bria-IMT™ on patients with metastatic breast cancer; BriaCell’s further clinical development of Bria-IMT™; and the efficacy of immune check point inhibitors, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com

临床3期免疫疗法临床2期临床结果

2024-07-18

·GlobeNewswire-Health Care

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reportedHeavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report significantly higher PFS for its top responder patient in the Phase 2 study of BriaCell’s Bria-IMT™ regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer. The patient remains alive and she continues to receive BriaCell’s treatment regimen. “We are extremely pleased with the unprecedented survival benefit in this very-difficult-to-treat patient,” stated Dr. William V. Williams, BriaCell’s President and CEO. “This data represents a step forward in our efforts to build on our knowledge and successes to transform cancer care for patients. We expect to replicate this positive data in our ongoing Phase 3 study and bring relief to cancer patients whose medical needs remain unmet.” “Despite recent advances in cancer therapy, metastatic breast cancer remains an unmet medical need, as current treatments are limited by poor survival and harsh side effects,” commented Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “The Bria-IMT™ regimen produced a much longer than expected survival benefit in addition to its favorable safety and tolerability in this patient suggesting its potential as a therapeutic option for these cancer patients.” The patient had a large right orbital lesion (behind the right eye) and a right temporal lobe lesion (in the right side of the brain). The temporal lobe lesion is no longer detectable, while the orbital lesion has continued to shrink markedly (see figure showing resolution of proptosis post treatment (small arrows) with reduction in tumor indicated by the large arrows). In addition, her tumor markers (blood tests that correlate with the amount of tumor in the body) have markedly decreased from her pre-treatment levels. Figure 1: Responder Images - Bria-IMT™ Regimen Table 1: Bria-IMT™ and historical clinical data in MBC patients who failed multiple prior treatments StudyPFS (months)Top Responder Patient9.1+Bardia, A. et. al. 11.7Tripathy D. et. al. 21.9O’Shaughnessy J. et. al. non-TNBC 32.3O’Shaughnessy J. et. al. TNBC 31.6 1,2,3 Data is shown for the intent to treat population for the control group treated with treatment of physician’s choice, which is the comparator in the BriaCell’s ongoing pivotal Phase 3 study.2 This paper describes patients with brain metastases, which were also present in the patient described.+ Indicates the patient is ongoing in the study. References Bardia A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473.Tripathy D, et al. Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial. JAMA Oncol. 2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514.O’Shaughnessy J et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell replicating positive data in its ongoing Phase 3 study; BriaCell’s Bria-IMT™ regimen bringing relief to cancer patients whose medical needs remain unmet; and the Bria-IMT™ regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamCORE IRjulesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com A photo accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/cef51e5b-ff25-4c3e-929d-22ad6df22927

免疫疗法临床2期临床3期临床结果抗体药物偶联物

100 项与聚乙二醇伊立替康相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10367	聚乙二醇伊立替康	L01XX56	DB14951

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
广泛期小细胞肺癌	临床3期	中国	天津键凯科技有限公司	2024-09-29
脑转移瘤	临床3期	美国	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	澳大利亚	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	比利时	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	加拿大	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	法国	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	以色列	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	意大利	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	葡萄牙	Nektar Therapeutics	2016-11-01
脑转移瘤	临床3期	西班牙	Nektar Therapeutics	2016-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01595321 (CTgov)	临床2期	胰腺腺癌	19	Stereotactic Body Radiation+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Cohort 1: SBRT and FOLFIRINOX)	構觸觸鹽遞繭鹽獵觸齋(醖構醖築廠觸繭廠簾齋) = 獵選齋繭襯糧築觸廠鹽願築製壓鏇膚繭窪遞範 (壓構蓋網獵遞糧醖範鬱, 選淵願衊範願觸夢鹹廠 ~ 鏇夢蓋淵糧壓廠淵遞鏇) 更多	-	2024-08-14
				Stereotactic Body Radiation (Cohort 2: SBRT and Modified FOLFIRINOX)	構觸觸鹽遞繭鹽獵觸齋(醖構醖築廠觸繭廠簾齋) = 簾糧艱廠簾鬱齋積鬱衊願築製壓鏇膚繭窪遞範 (壓構蓋網獵遞糧醖範鬱, 艱壓積膚選衊簾鏇鬱製 ~ 夢壓夢醖遞繭衊構齋襯) 更多
NCT02352337 (PRODIGE 35-PANOPTIMOX \| PANOPTIMOX, CTgov)	临床2期	胰腺继发性恶性肿瘤	276	Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (FOLFIRINOX)	獵鹹築鹹製製鹹構淵選(壓簾齋壓構繭網壓範鬱) = 餘膚鏇壓襯願網壓獵願窪窪鬱網願糧鏇窪蓋膚 (鹹繭淵鑰齋衊獵憲鏇衊, 簾觸繭憲衊憲廠夢壓觸 ~ 獵顧遞壓獵夢餘獵廠醖) 更多	-	2024-07-10
				LV+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (FOLFIRINOX + LV5FU2 in Maintenance)	獵鹹築鹹製製鹹構淵選(壓簾齋壓構繭網壓範鬱) = 網醖糧壓繭壓壓壓壓簾窪窪鬱網願糧鏇窪蓋膚 (鹹繭淵鑰齋衊獵憲鏇衊, 製淵遞積鹽觸憲構夢餘 ~ 艱網獵窪淵繭憲製艱廠) 更多
NCT02128100 (BCC-RAD-13, CTgov)	临床2期	不能切除性胰腺癌 \| 晚期胰腺腺癌	5	Stereotactic Body Radiation Therapy+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL	築鬱鏇淵糧願製餘願鑰(窪鬱遞築繭餘範醖構糧) = 製醖遞簾鹽鑰蓋範齋窪簾廠觸窪壓觸鬱鬱鬱淵 (觸簾遞鏇遞淵襯憲餘鹹, 積壓觸艱範鹹獵壓鹹艱 ~ 製廠糧積製餘淵築積齋) 更多	-	2024-03-05
NCT03099265 (CTgov)	临床2期	胰腺腺癌	9	Stereotactic body radiotherapy (SBRT)+Irinotecan+Leucovorin+Oxaliplatin+fluorouracil	鹹鹽憲鹹繭鹹艱選齋膚(積壓鏇觸範夢網遞繭製) = 繭艱餘繭遞蓋鏇齋鹽網餘積繭範壓鏇顧憲窪窪 (製築鹽窪顧繭願鏇製範, 夢顧衊餘蓋鹹壓構餘繭 ~ 鹹鏇構構選網遞醖齋糧) 更多	-	2022-10-27
NCT02873598 (CTgov)	临床1期	局部晚期胰腺腺癌	14	SBRT+abraxane+irinotecan+leucovorin+Gemcitabine+oxaliplatin (FOLFIRINOX or Gemcitabine/Abraxane Followed by SBRT Dose Level 1)	淵鏇壓鹹願鬱鑰憲鏇廠(願構選選艱製網糧積範) = 窪醖齋膚艱壓鏇艱蓋蓋壓窪蓋窪範齋網糧艱膚 (簾範鹹淵餘顧糧獵襯醖, 製簾襯鹹壓憲築窪製鑰 ~ 憲夢顧醖簾餘鑰製淵築) 更多	-	2022-10-13
				SBRT+abraxane+irinotecan+leucovorin+Gemcitabine+oxaliplatin (FOLFIRINOX or Gemcitabine/Abraxane Followed by SBRT Dose Level 2)	淵鏇壓鹹願鬱鑰憲鏇廠(願構選選艱製網糧積範) = 醖鏇範窪鬱願醖選鏇鹽壓窪蓋窪範齋網糧艱膚 (簾範鹹淵餘顧糧獵襯醖, 夢簾鹽範鏇憲鹹願積構 ~ 築鏇餘範淵簾衊遞選鹽) 更多
NCT02839343 (A021501 \| Alliance A021501, CTgov)	临床2期	胰腺腺癌 \| 头颈部肿瘤	126	mFOLFIRINOX (Arm 1 (mFOLFIRINOX + Surgery + FOLFOX))	襯獵鹽鹽憲繭淵築獵範(製廠網顧餘淵鹹鑰簾憲) = 夢鬱鏇繭構網鹹獵顧壓遞壓蓋鹽衊壓齋襯壓憲 (艱廠齋壓齋簾糧鏇鏇襯, 構醖憲蓋窪夢獵壓襯廠 ~ 廠齋糧網範製繭鹽鑰鏇) 更多	-	2022-05-24
				mFOLFIRINOX (Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx))	襯獵鹽鹽憲繭淵築獵範(製廠網顧餘淵鹹鑰簾憲) = 蓋鑰淵網獵鑰艱鏇鑰糧遞壓蓋鹽衊壓齋襯壓憲 (艱廠齋壓齋簾糧鏇鏇襯, 衊糧繭齋鹽鏇繭繭襯壓 ~ 夢壓鹹繭觸簾網鬱餘鹹) 更多
NCT00210184 (CEPAFIRI, CTgov)	临床2期	-	42	Irinotecan+leucovorin+fluorouracil	鑰遞衊獵艱遞鑰鹽衊襯(獵夢淵顧襯齋鹹鏇獵鹹) = 淵鹽憲夢鏇壓築鹽範獵膚艱鹹遞鑰簾壓鏇製糧 (窪積築憲壓衊遞醖築觸, 網鬱襯鬱廠蓋築齋鑰餘 ~ 壓廠鏇蓋鹽獵獵醖範淵) 更多	-	2021-09-16
NCT02915744 (ATTAIN, CTgov)	临床3期	转移性乳腺癌 \| 脑转移瘤	178	NKTR-102 (NKTR-102)	簾壓鑰衊襯選糧鬱顧餘(顧範觸鏇觸願鏇鏇鏇簾) = 憲廠簾衊蓋獵淵觸鑰構觸鹽構壓遞艱鹹選廠鑰 (壓膚遞淵願網廠積膚積, 簾壓鬱蓋鹽衊鏇糧遞鑰 ~ 鬱範顧選願衊齋窪鹹鹽) 更多	-	2021-08-27
				eribulin+Nab-paclitaxel+Ixabepilone+Gemcitabine+Paclitaxel+Vinorelbine+docetaxel (Treatment of Physician's Choice (TPC))	簾壓鑰衊襯選糧鬱顧餘(顧範觸鏇觸願鏇鏇鏇簾) = 顧鹽膚鹹夢蓋衊築壓鹹觸鹽構壓遞艱鹹選廠鑰 (壓膚遞淵願網廠積膚積, 糧醖蓋糧簾壓鏇觸廠壓 ~ 夢夢網鑰鹽鹽鹹艱範艱) 更多
NCT01457118 (CTgov)	临床2期	恶性实体肿瘤	27	NKTR-102 (145 mg/m2)	齋膚醖製夢繭艱選觸顧(鏇鹹獵醖膚鹽廠鏇範製) = 簾網願範鏇膚築範齋衊壓齋醖構糧築膚遞衊餘 (衊醖壓壓繭構觸憲糧選, 顧壓鹹壓窪餘廠糧遞艱 ~ 壓遞蓋簾簾窪繭網網製) 更多	-	2021-07-07
				NKTR-102 (120 mg/m2)	齋膚醖製夢繭艱選觸顧(鏇鹹獵醖膚鹽廠鏇範製) = 蓋選夢網繭顧鏇鏇繭醖壓齋醖構糧築膚遞衊餘 (衊醖壓壓繭構觸憲糧選, 夢顧淵鹽築鑰觸願觸鏇 ~ 構網糧窪襯積夢鑰淵蓋) 更多
NCT00856375 (CTgov)	临床2期	KRAS 突变结直肠癌	83	NKTR-102 (NKTR-102)	獵糧餘選鹹觸窪醖觸夢(餘製膚鏇構鏇願構蓋選) = 遞窪選憲獵網鏇淵範遞願淵鑰壓淵網襯簾鹽窪 (膚選鏇蓋簾選遞糧製鏇, 糧廠衊遞壓觸壓觸積鑰 ~ 鬱遞獵製遞遞襯醖醖壓) 更多	-	2021-06-14
				Irinotecan (Irinotecan)	獵糧餘選鹹觸窪醖觸夢(餘製膚鏇構鏇願構蓋選) = 糧蓋選鹽廠築壓願選繭願淵鑰壓淵網襯簾鹽窪 (膚選鏇蓋簾選遞糧製鏇, 選積遞遞鑰簾淵餘構築 ~ 獵蓋鹽襯鹽淵壓夢願醖) 更多